Back

HELIOS-B - Primary results from phase 3 study of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy

30 August 2024 (11:00 - 11:12)
Organised by: Logo
Congress Presentation Part of: HOT LINE 1 Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Marianna Fontana

University College London, London (United Kingdom of Great Britain & Northern Ireland)

8 More presentations in this session

Presentation thumbnail
Discussant review - HELIOS-B
Doctor S. Cuddy (Boston, US)
Slides Video
Presentation thumbnail
Panel discussion - HELIOS-B
Video
Presentation thumbnail
Beta blocker interruption in patients with prior myocardial infarction: results of the ABYSS trial and effect on blood pressure and heart rate control
Professor J. Silvain (Paris, FR)
Slides Video
Presentation thumbnail
Discussant review - ABYSS
Professor J. Armitage (Oxford, GB)
Slides Video
Presentation thumbnail
Panel discussion - ABYSS
Video

Access the full session

Session thumbnail
HOT LINE 1
Video

The Event

Event poster

ESC Congress 2024

30 August 2024 11:00 CET
You may be interested in
thumbnail
Congress Presentation
Highlights from HELIOS-B - Primary results from phase 3 study of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy
thumbnail
Congress Presentation
HELIOS-B: Vutrisiran reduces all-cause mortality
thumbnail
Congress Presentation
Highlights from HELIOS-B - Primary results from phase 3 study of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources